COVID-19 vaccination in Japan

Last updated
COVID-19 vaccination in Japan
Japan map of fully vaccinated people by percentage of population by prefecture as of 23rd of June 2021.png
Japan map by prefecture. Percentage of people got fully vaccinated by population as of 6rd of November 2021. [1]
Date17 February 2021 (2021-02-17) – present
LocationJapan
Cause COVID-19 pandemic in Japan
TargetFull immunisation of people in Japan against COVID-19
Organised by Ministry of Health, Labour and Welfare
Participants77,098,247 people have received at least one vaccine dose
(7 September 2021)
61,995,078 have been fully vaccinated (received both vaccine doses, 7 September 2021) [2] [3]
Outcome49.4% of the Japanese population has received their first dose of a two-dose vaccine
39.1% has been fully vaccinated
Website Novel Coronavirus (COVID-19) information
Yoshihide Suga, the prime minister of Japan vaccinated with COVID-19 COVID-19wakuchin(huaizaZhi )noJie Zhong woXing uJian Yi Wei Shou Xiang 4.jpg
Yoshihide Suga, the prime minister of Japan vaccinated with COVID-19

COVID-19 vaccination in Japan started later than in most other major economies. [4] The country has frequently been regarded "slow" for its vaccination efforts. [5] [6]

Contents

Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. As of mid-August 2021, around 46 million [ citation needed ] people have been fully vaccinated in the country.

Background

On 14 February 2021, Pfizer was approved by the government of Japan, [7] and was deployed on 17 February 2021. [8] On 28 May 2021, Pfizer was approved by the Japanese health ministry panel for adolescents aged between 12 and 15 years. [9]

On 21 May 2021, Moderna and Astrazeneca were approved by the government of Japan. [10]

Vaccines on order

VaccineApprovalDeploymentDoses secured
(million) [11]
Pfizer–BioNTech Green check.svg 14 February 2021Green check.svg 17 February 2021194
Moderna Green check.svg 21 May 2021 [10] Green check.svg 23 May 2021 [12] 100 [13] [14]
Oxford–AstraZeneca Green check.svg 21 May 2021 [10] Green check.svg 16 August 2021 [15] 120
Janssen Pending [16] Dark Red x.svg Not Yet
Novavax PendingDark Red x.svg Not Yet150 [17]

Note: Japan has donated 1.24 million doses of AstraZeneca vaccine to Taiwan and 1 million doses to Vietnam. There are plans to send additional 2 million doses to these countries. Japan has also donated 1 million doses each to Thailand, Malaysia, Indonesia and the Philippines. [18] Japan also donates over 2 million doses of AstraZeneca Vaccine to Iran through COVAX. [19]

Vaccines in trial stage

VaccineCountry of originType (technology)ProgressRef
AG0302-COVID‑19
AnGes Inc., AMED
Japan DNA vaccine (plasmid)Phase II–III (500)
Randomized, double-blind, placebo controlled
Nov 2020 Apr 2021, Japan
[20] [21] [22] [23]
S-268019
Shionogi
Japan Subunit Phase I–II (214)
Randomized, double-blind, placebo-controlled, parallel-group.
Dec 2020 Jun 2022, Japan
[24]
DS-5670
Daiichi Sankyo
Japan RNA Phase I–II (152)
A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects.
Mar 2021 Jul 2022, Japan
[25] [26] [27]
KD-414
KM Biologics Co
Japan Inactivated SARS‑CoV‑2 Phase I–II (210)
Randomized, double blind, placebo control, parallel group.
Mar 2021  Dec 2022, Japan
[28] [29]
EXG-5003
Elixirgen Therapeutics, Fujita Health University
Japan, United States RNA Phase I–II (60)
First in Human, randomized, placebo-controlled.
Apr 2021 Jan 2023, Japan
[30]

History

In April 2021, prime minister Suga Yoshihide announced that Japan will receive 50-million doses of the Pfizer vaccine after a meeting with the company's CEO. [4] [31]

The roll out of the vaccines in Japan, with 4 percent of the population inoculated as of May 21, 2021, has led to criticisms on slow approval, disruptions on import, and the lack of medical professionals. [32] [33] A poll conducted in April showed that more than 60 percent of people were dissatisfied with Japan’s vaccine rollout, with experts stating that it was too late now to stop the spread of variants with vaccines. [34]

Distribution issues

2020 Summer Olympics

Related Research Articles

The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health, the TGA regulates the quality, supply and advertising of medicines, pathology devices, medical devices, blood products and most other therapeutics. Any items that claim to have a therapeutic effect, are involved in the administration of medication, or are otherwise covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order, must be approved by the TGA and registered in the Australian Register of Therapeutic Goods.

Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Italy Immunization plan against COVID-19 in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

COVID-19 vaccination in Albania

The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.

COVID-19 vaccination in Canada COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020 and is currently ongoing.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.

The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.

COVID-19 vaccination in Vietnam Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

COVID-19 vaccination in South Korea Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Indonesia

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks fifth in the world and second in Asia.

The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.

COVID-19 vaccination in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

COVID-19 vaccination in Nepal Immunisation programme against COVID-19 in Nepal

Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said “We will export vaccines taking into account the domestic demand.” By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."

COVID-19 vaccination in Sri Lanka Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

COVID-19 vaccination in Taiwan Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.

COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

References

  1. Japan COVID-19 Vaccine Tracker: Prefectures Map. By George Karabassis. Click on the 1M and 2x buttons on the bottom right of the map to produce the map shown above.
  2. "Ongoing Topics - Novel Coronavirus Vaccines". Prime Minister of Japan and His Cabinet. 8 September 2021. Retrieved 9 September 2021.
  3. "新型コロナワクチンについて".
  4. 1 2 Kanishka Singh (2021-04-18). "UPDATE 1-Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan" . Retrieved 2021-05-25.
  5. "Japan's slow vaccination process as Tokyo 2020 looms". CNN. April 26, 2021. Retrieved 2021-05-25.
  6. Blake Essig, Emiko Jozuka and Ben Westcott (April 14, 2021). "With 100 days until the Tokyo Olympics, Japan has vaccinated less than 1% of its population. That's a problem". CNN. Retrieved 2021-05-25.
  7. "Japan approves Pfizer's COVID-19 vaccine, 1st for domestic use". Nikkei Asia . 14 February 2021. Retrieved 14 February 2021.
  8. "Japan gives first COVID-19 vaccinations to Tokyo health workers". The Japan Times. 17 February 2021. Retrieved 31 May 2021.
  9. "Japan to approve Pfizer COVID-19 vaccine for 12- to 15-year-olds". Kyodo News. 28 May 2021. Retrieved 31 May 2021.
  10. 1 2 3 "Japan issues final approval for Moderna and AstraZeneca vaccines". The Japan Times. 2021-05-21.
  11. "Japan gives preliminary OK to 2 more COVID-19 vaccines". Associated Press. May 20, 2021.
  12. "自衛隊員にモデルナ製ワクチン 国内初、大規模接種会場を運営". Tokyo Shimbun. 23 May 2021. Retrieved 2 June 2021.
  13. "新型コロナウイルスワクチンの供給に係るモデルナ社及び武田薬品工業株式会社との契約締結について" (PDF). Ministry of Health, Labour and Welfare. October 29, 2020.
  14. "新型コロナウイルスワクチンの来年に向けた供給に係る武田薬品工業株式会社及びモデルナ社との契約締結について". Ministry of Health, Labour and Welfare. July 20, 2021.
  15. "Japan begins using AstraZeneca vaccine in bid to step up inoculations". The Japan Times. 23 August 2021. Retrieved 23 August 2021.
  16. "Johnson & Johnson seeks COVID-19 vaccine approval in Japan". The Japan Times. 25 May 2021. Retrieved 28 August 2021.
  17. "来年の新型コロナワクチンの供給に係る武田薬品工業株式会社との契約締結について". Ministry of Health, Labour and Welfare. September 7, 2021.
  18. "Japan to give 6 mln doses of vaccines to Taiwan, 5 SE Asia nations". Reuters. June 25, 2021.
  19. "Japan Donates over 2 Million Doses of AstraZeneca Vaccine to Iran through COVAX - Society/Culture news". Tasnim News Agency. Retrieved 2021-09-23.
  20. "About AnGes – Introduction". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  21. "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov . United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  22. "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.
  23. "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.
  24. "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 21 March 2021.
  25. "Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan" (PDF) (Press release). Daiichi Sankyo. Retrieved 17 April 2021.
  26. "Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up". Fierce Biotech. March 22, 2021. Retrieved 12 April 2021.
  27. "Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects". clinicaltrials.gov. United States National Library of Medicine. Retrieved 12 April 2021.
  28. "Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 22 March 2021.
  29. "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン(KD-414)の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 7 May 2021.
  30. "Safety and Immunogenicity of EXG-5003". clinicaltrials.gov. United States National Library of Medicine. Retrieved 2 May 2021.
  31. "Japan to receive 50 mil. additional doses of Pfizer vaccine". April 21, 2021. Retrieved 2021-05-25.
  32. Kosaka, Makoto; Hashimoto, Takanao; Ozaki, Akihiko; Tanimoto, Tetsuya; Kami, Masahiro (2021-06-02). "Delayed COVID-19 vaccine roll-out in Japan". The Lancet. 397 (10292): 2334–2335. doi:10.1016/S0140-6736(21)01220-4. ISSN   0140-6736. PMC   8172150 . PMID   34089658.
  33. "EXPLAINER: Why Japan has been slow to roll out vaccinations". The Asahi Shimbun. Retrieved 2021-06-08.
  34. McCurry, Justin (26 April 2021). "Japan's slow Covid vaccine rollout casts cloud over Olympics". The Guardian . Retrieved 8 June 2021.